• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

马拉维若与依非韦伦联合齐多夫定/拉米夫定治疗对初治 HIV 感染者 CD4/CD8 比值的影响。

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.

机构信息

Department of Infectious Diseases, Hospital Universitario Ramon y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain

Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.

出版信息

Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01763-17. Print 2017 Dec.

DOI:10.1128/AAC.01763-17
PMID:28993335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5700350/
Abstract

A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8 T-cell decline.

摘要

在治疗后的 HIV 感染中，CD4/CD8 比值较低反映了免疫激活增强，并预测死亡。不同抗逆转录病毒治疗方案对 CD4/CD8 比值恢复的影响尚不清楚。我们对 MERIT 研究进行了 分析，该研究是一项在初治 HIV 感染者中比较马拉维若与依非韦伦联合齐多夫定-拉米夫定的随机、双盲试验。我们发现依非韦伦组的 CD4/CD8 比值正常化率更高，这是由于 CD8 T 细胞下降更大所致。

相似文献

1
Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.马拉维若与依非韦伦联合齐多夫定/拉米夫定治疗对初治 HIV 感染者 CD4/CD8 比值的影响。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01763-17. Print 2017 Dec.
2
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.马拉维若与依非韦伦，联合齐多夫定-拉米夫定，用于治疗 CCR5 嗜性 HIV-1 感染的抗逆转录病毒初治患者。
J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697.
3
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.与依法韦仑相比，马拉维若联合齐多夫定/拉米夫定的疗效和安全性：MERIT研究的96周结果
HIV Clin Trials. 2010 May-Jun;11(3):125-32. doi: 10.1310/hct1103-125.
4
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.马拉维若与依非韦伦治疗初治HIV-1患者的疗效和安全性：5年研究结果
AIDS. 2014 Mar 13;28(5):717-25. doi: 10.1097/QAD.0000000000000131.
5
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.在伊朗接受一线治疗的HIV阳性患者中，使用含福沙那韦或齐多夫定/拉米夫定/依非韦伦的抗逆转录病毒方案实现不同程度的免疫恢复。
Infect Disord Drug Targets. 2018;18(3):207-213. doi: 10.2174/1871526518666180108104031.
6
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.对于初治的HIV感染成人患者，采用拉米夫定/齐多夫定复方片剂联合阿巴卡韦和依非韦伦进行紧凑四联疗法，随后使用拉米夫定/齐多夫定/阿巴卡韦三联核苷片剂联合依非韦伦。
HIV Clin Trials. 2003 Jul-Aug;4(4):231-43. doi: 10.1310/MM9W-BAU0-BT6Q-401B.
7
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.96周的MERIT ES分析显示了Celsentri（=Selzentry）的疗效。
AIDS Patient Care STDS. 2009 Aug;23(8):679. doi: 10.1089/apc.2009.9921.
8
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.去羟肌苷、拉米夫定和依非韦伦与齐多夫定、拉米夫定和依非韦伦用于西班牙VACH队列中HIV感染患者初始治疗的有效性和安全性比较
J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6.
9
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.维克立罗与依非韦伦（均联合齐多夫定/拉米夫定）用于初治HIV-1感染受试者的II期研究。
J Infect Dis. 2008 Oct 15;198(8):1113-22. doi: 10.1086/592052.
10
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.阿巴卡韦与齐多夫定联合拉米夫定和依非韦伦治疗初治的成人HIV感染者的比较。
Clin Infect Dis. 2004 Oct 1;39(7):1038-46. doi: 10.1086/424009. Epub 2004 Sep 10.

引用本文的文献

1
The clinical indexes and immunological status of HIV/AIDS patients undergoing different highly active antiretroviral treatments.接受不同高效抗逆转录病毒治疗的HIV/AIDS患者的临床指标和免疫状态。
Front Cell Infect Microbiol. 2024 Dec 17;14:1436123. doi: 10.3389/fcimb.2024.1436123. eCollection 2024.
2
Analysis of the expression characteristics and clinical value of immune function indicators in patients with human immunodeficiency virus infection.人类免疫缺陷病毒感染患者免疫功能指标的表达特征及临床价值分析
Pak J Med Sci. 2024 Nov;40(10):2233-2237. doi: 10.12669/pjms.40.10.9895.
3
CD4/CD8 Ratio Recovered as a Predictor of Decreased Liver Damage in Adults Infected With HIV: 16-Year Observational Cohort Study.CD4/CD8 比值恢复可预测 HIV 感染者肝损伤减轻：16 年观察性队列研究。
JMIR Public Health Surveill. 2024 Jan 9;10:e45818. doi: 10.2196/45818.
4
Association Between CD4/CD8 Ratio Recovery and Chronic Kidney Disease Among Human Immunodeficiency Virus-Infected Patients Receiving Antiretroviral Therapy: A 17-Year Observational Cohort Study.接受抗逆转录病毒治疗的人类免疫缺陷病毒感染患者中CD4/CD8比值恢复与慢性肾脏病的关联：一项17年的观察性队列研究
Front Microbiol. 2022 Feb 10;13:827689. doi: 10.3389/fmicb.2022.827689. eCollection 2022.
5
Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?用于治疗HIV感染的联合抗逆转录病毒疗法方案是否具有多样的T细胞表型和炎症特征？
Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa340. doi: 10.1093/ofid/ofaa340. eCollection 2020 Sep.
6
Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4:CD8 T-cell ratio in treated HIV-1 infection.干扰素 lambda rs368234815ΔG/ΔG 与治疗后 HIV-1 感染中更高的 CD4:CD8 T 细胞比值相关。
AIDS Res Ther. 2020 Apr 15;17(1):13. doi: 10.1186/s12981-020-00269-0.
7
Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort.一线抗逆转录病毒疗法方案对 CNICS 队列中 CD4/CD8 比值恢复的影响。
J Antimicrob Chemother. 2020 Jun 1;75(6):1604-1610. doi: 10.1093/jac/dkaa024.
8
CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.CCR5/CXCR4 双重拮抗剂用于改善 HIV 感染治疗。
Molecules. 2019 Feb 2;24(3):550. doi: 10.3390/molecules24030550.

本文引用的文献

1
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.CCR5 拮抗剂马拉维若单独或与 PKC 激动剂波莱霉素 1 联合使用，可逆转体外 HIV-1 潜伏期。
Sci Rep. 2017 May 24;7(1):2385. doi: 10.1038/s41598-017-02634-y.
2
Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.早期HIV感染期间强化抗逆转录病毒疗法对肠道免疫学和炎症性血液生物标志物的影响。
AIDS. 2017 Jul 17;31(11):1529-1534. doi: 10.1097/QAD.0000000000001515.
3
Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir.简短通讯：马拉维若强化治疗对血液和肠道病毒库无影响
AIDS Res Hum Retroviruses. 2017 Feb;33(2):143-146. doi: 10.1089/AID.2016.0198.
4
Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.与替诺福韦相比，马拉维若可使CD4 +细胞计数差异增加，CD4 + ：CD8 +比值恢复正常。
AIDS. 2016 Aug 24;30(13):2091-7. doi: 10.1097/QAD.0000000000001181.
5
Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care.缩小接受治疗的HIV感染者与未感染HIV个体之间的预期寿命差距。
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):39-46. doi: 10.1097/QAI.0000000000001014.
6
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.马拉维若强化联合抗逆转录病毒疗法可改善病毒抑制的HIV相关神经认知障碍患者的认知功能。
AIDS. 2016 Feb 20;30(4):591-600. doi: 10.1097/QAD.0000000000000951.
7
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.基于CCR5/整合酶抑制剂联合方案对初治HIV感染患者黏膜免疫的影响：一项试点随机试验
PLoS Pathog. 2016 Jan 21;12(1):e1005381. doi: 10.1371/journal.ppat.1005381. eCollection 2016 Jan.
8
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.在接受抗逆转录病毒治疗实现病毒载量抑制的 HIV 感染者中，CD4/CD8 比值正常化与非艾滋病相关事件：一项观察性队列研究。
Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6.
9
Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.在HIV感染个体中，基于整合酶抑制剂的初始抗逆转录病毒疗法对单核细胞激活和血管炎症的差异降低作用
J Infect Dis. 2015 Aug 1;212(3):345-54. doi: 10.1093/infdis/jiv004. Epub 2015 Jan 12.
10
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals.大量HIV感染个体队列中CD8 + T细胞计数的病程及临床意义
J Infect Dis. 2015 Jun 1;211(11):1726-34. doi: 10.1093/infdis/jiu669. Epub 2014 Dec 8.